According to the results of a large international study, the antiviral drug remdesivir does not reduce mortality in COVID-19 patients compared to standard treatment.
The Food and Drug Administration will treat COVID-19 with remdesivir in an emergency in May after a large clinical trial suggests that COVID-19 patients will take less time to be discharged. I approved that. Compared to placebo treatment Live Science previously reported.. As of August, the drug has been approved for use in all patients admitted with COVID-19, not just those receiving oxygen supplementation. The New York Times reported.. Thousands of US patients, including the president, were treated.
But now, a large World Health Organization-sponsored study suggests that remdesivir does not reduce the risk of patients dying from COVID-19 the month after treatment.The study was posted to the preprint database on October 15th. medRxiv Not yet peer reviewed. More than 11,200 people from 30 countries participated. Reported Times..
Relation: 20 of the worst fads and pandemics ever
Approximately 4,100 of those patients acted as a comparison group and were not receiving medication, while the rest received one of the four medications, or a combination of several medications. These drugs contained remdesivir, Hydroxychloroquine, An antiviral agent called lopinavir and an immunostimulatory molecule called interferon-β1a. Approximately 650 patients received interferon and lopinavir together.
Ultimately, the study results suggest that a single drug or combination of drugs did not significantly reduce patient mortality compared to the drug-free group. In addition, these drugs did not reduce the likelihood that the treated patient would be placed on a ventilator, nor did they reduce the patient’s hospital stay.
“The unlikely overall findings from the tested regimen are sufficient to refute early hopes,” the study authors wrote that the drug would reduce mortality in COVID-19 patients. Earlier studies have already shown that hydroxychloroquine and ropinavir do not reduce mortality, but data on remdesivir provide new insights into whether the drug actually works. According to the Associated Press..
Relation: Treatment for COVID-19: Drugs tested against coronavirus
“The big story is the discovery that remdesivir has no meaningful impact on survival,” Martin Landley, a professor of medicine and epidemiology at Oxford University, said in a statement, according to the Associated Press. However, Dr. Peter Chin Hong, an infectious disease expert at the University of California, San Francisco, told The New York Times that the test results could be somewhat distorted.
He said that factors other than remdesivir may have affected patient survival, as study participants were treated in 405 different hospitals around the world, each with their own treatment protocol.In addition, remdesivir can benefit patients even when given early In the process of their illness, but it was not specifically addressed by a new study, Dr. Marika Marinis, an infectious disease doctor at Yale University, told the Times.
But even if remdesivir helped some patients, it was still expensive and difficult to administer, Randley said in a statement. “This is a drug that must be given by intravenous infusion for 5 to 10 days,” he said, which costs about $ 2,550 per course of treatment. (The cost of a US private insurance patient treatment course is $ 3,120, The Times reports.)
“COVID affects millions of people and their families around the world. We need scalable, affordable and equitable treatment,” says Landray.
Originally published in Live Science.